;)
July 20th, 2023When it comes to over-the-counter pain relievers, Tylenol has long been considered a trusted ally in combating aches and pains. Its wide availability and reputation have made it a go-to choice for many. However, behind this seemingly innocent remedy lies an unsettling link between Tylenol and the severe skin disorder Stevens-Johnson Syndrome. A new study has examined the increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when taking acetaminophen. These emergency skin disorders can have dire consequences, including blindness and death.
SJS and TEN are severe and rare skin disorders characterized by a range of distressing symptoms. SJS typically begins with flu-like symptoms, but quickly a painful rash develops. This rash then progresses into blisters and painful sores, causing the top layer of the skin to separate from the underlying tissues.
When the condition progresses to TEN, it is considered a medical emergency. TEN causes widespread skin detachment, leaving large areas prone to infection. The skin becomes highly susceptible to secondary infections, and patients may also experience eye inflammation, leading to vision problems or even blindness. Patients with extensive skin detachment are at high risk of fluid loss, infection, and organ failure, necessitating close monitoring and intensive medical support.
Around 9.2 million cases of SJS and 1.9 million cases of TEN are reported in the United States annually, with morbidity rates for SJS and TENS reported as 4.8-9% and 14.8-48%, respectively.
While SJS has been associated with anticonvulsants, antibiotics, and non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen has consistently emerged as one of the most widely cited causes. The FDA took action in 2013 and required new label warnings for Tylenol and other acetaminophen drugs. These warnings aimed to alert healthcare providers and consumers about the possible association between acetaminophen and SJS.
A recent study conducted by researchers from Louisiana State University has shed further light on acetaminophen’s role in SJS. Their findings revealed that acetaminophen accounted for more than 5% of all SJS and toxic epidermal necrolysis (TEN) cases. Therefore, acetaminophen is the third-largest contributor to SJS/TEN. The study also indicated a higher correlation between acetaminophen use and these severe skin reactions in certain populations. For example, individuals with specific genetic predispositions may be more susceptible, notably Asian populations.
Although SJS and TEN are rare, the study emphasized that it is important that physicians and patients recognize the risk of acetaminophen-related reactions. Additionally, the study called for more clinical trials to further examine the relationship between Tylenol and Stevens-Johnson Syndrome.
The potential connection between Tylenol and Stevens-Johnson Syndrome has prompted victims and their families to file lawsuits seeking compensation for their injuries, medical expenses, and pain and suffering.
Individuals have filed Stevens-Johnson Syndrome lawsuits against Tylenol manufacturers, like Johnson & Johnson, alleging they failed to adequately warn consumers about the potential risks of developing SJS and its more severe form, toxic epidermal necrolysis (TEN). Plaintiffs argue that if they had been aware of the potential dangers, they would have chosen alternative pain relief options.
However, Tylenol’s legal battles do not end there. Individuals are also filing acetaminophen ADHD and autism lawsuits against Johnson & Johnson. These lawsuits claim that prenatal exposure to acetaminophen can increase the risk of neurological disorders in children, like ADHD and autism.
If you or a loved one developed SJS/TEN after taking acetaminophen, you may be eligible to file a lawsuit. The Lake Law Firm is supporting those affected by this alarming and potentially life-threatening disorder. Call (888) 525-3529 today to see if you qualify for financial compensation in a Stevens-Johnson Syndrome lawsuit.
The Lake Law Firm
N/a
